This cluster reflects a convergent trend in geroscience and aging research: the use of machine learning and deep learning to convert routine, low-cost biological data—standard blood panels and proteomics—into actionable phenotypes and composite scores that stratify risk for mortality, frailty, cognitive impairment, and chronic disease. The Toledo Study for Healthy Ageing exemplifies this by applying unsupervised machine learning to 39 routine blood biomarkers from community-dwelling older adults, yielding three biochemical phenotypes (Metabolic, Haematological, Healthy) with distinct 10-year trajectories—most notably a sex-specific elevated mortality risk (HR=1.49) in women with the Metabolic Phenotype, replicated independently in the EXERNET cohort. In parallel, the SASP Score demonstrates how deep learning applied to UK Biobank proteomics can distill systemic cellular senescence burden into a single geroscience biomarker that predicts mortality, dementia, COPD, myocardial infarction, and stroke, while remaining responsive to exercise intervention in a randomized controlled trial—positioning it as both a prognostic and a monitorable, modifiable target.
A second thread connects functional and behavioral markers—grip strength, gait speed, physical function—to psychosocial and cognitive outcomes. Frailty, depression, and cognitive impairment are tightly interlinked, with grip strength emerging as a mediator between frailty and incident depression, and gait speed identified as a screening/intervention target for cognitive decline. The "super movers" concept (exceptional gait speed) further shows that functional performance, rather than amyloid pathology (ruled out via postmortem examination), tracks with protection against memory and non-memory cognitive decline—suggesting non-amyloid, possibly vascular or systemic mechanisms underlie functional-cognitive resilience. Smoking and depression appear as modifiable behavioral risk factors compounding cognitive impairment risk, particularly in younger adults, tying lifestyle factors into the broader aging-risk architecture alongside biochemical and proteomic signatures.
Underlying both threads is a methodological tension: precision medicine's drive toward molecular stratification inherently produces small, rare-disease-sized cohorts that strain conventional machine learning and deep learning paradigms optimized for large training datasets, risking performance degradation upon deployment. The literature proposes federated learning, few-shot learning, and transfer learning as adaptations to preserve model validity and enable robust model deployment despite data scarcity. This positions the field at an inflection point: scalable, low-cost "precision prevention" using routine labs and proteomics is maturing as a population-level tool, even as the field grapples with extending these AI-driven approaches to smaller, more molecularly stratified patient subgroups without sacrificing reliability.
Together, these entities describe a trend toward biomarker-derived, AI-powered phenotyping that unifies systemic biology (senescence, metabolic/hematological dysfunction), functional status (grip strength, gait speed), and behavioral/psychiatric factors into integrated risk models—while simultaneously exposing the infrastructural and methodological adaptations needed to make such precision approaches scalable and clinically deployable.